Assesment for Responses to Cilnidipine in Diabetic Nephropathy with Hypertension

Assesment for Responses to Cilnidipine in Diabetic Nephropathy with Hypertension - Cilnidipine vs L-CCBs, Evaluation of Antihypertensive and Renoprotective Effects in Diabetic patients (CLEARED study)

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000000835

Enrollment

120

Registered

2007-10-15

Start date

2007-08-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic nephropathy with hypertension

Interventions

L-CCB/Cilnidipine group: Switch to 6 month-treatment with cilnidipine after L-CCB administration for at least 6 months Cilnidipine/L-CCB group: Switch to 6 month-treatment with L-CCB after cilnidipi

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with both conditions of (1) and (2). (1) Hypertensive patients with diabetic nephropathy. (2) Patients who need antihypertensive therapy with Ca-channel blocker.

Exclusion criteria

Exclusion criteria: (1) Contraindication to Ca-channel blocker (2) The patient who is judged to be inappropriate for this study by the doctor in charge.

Design outcomes

Primary

Measure	Time frame
1. Change in urinary excretion of albumin or protein 2. Change in serum creatinin level or GFR 3. Blood pressure lowering effects. Achievement of target blood pressure, <130/80 mmHg (<125/75 mmHg in case of more than 1g/day of urinary protein excretion)	—

Secondary

Measure	Time frame
Change in plasma glucose, HbA1C, insulin, total cholesterol, triglyceride, LDL-cholesterol, HDL-cholesterol, urinary NAG excretion, or blood AGE levels, urinary BMG.	—

Countries

Japan

Contacts

Public ContactShinya Fukumoto

Osaka City University Graduate School of Medicine Department of Metabolism, Endocrinology and Molecular Medicine

sfukumoto@med.osaka-cu.ac.jp06-6645-3806

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026